Skip to content

Cognitive decline in cancer: A cross-sectional study

Cancer-related cognitive impairment: Investigating cognition, psychosocial factors, and neurogenesis biomarkers.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12622001537741
Enrollment
38
Registered
2022-12-13
Start date
2023-11-03
Completion date
2024-12-01
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is investigating cancer-related cognitive impairment, and the impact of a cognitive training intervention. Who is it for? You may be eligible for this study if you are aged 18 years or over, living in or near the Perth/Peel regions of Western Australia, and are currently undergoing any treatment for a confirmed diagnosis of cancer. This study also needs healthy controls; that is, people aged 18 years or over, living in or near Perth/Peel regions of Western Australia, with no cancer diagnosis and no history of any cancer diagnosis. Study details Participants will be asked to complete tests of memory, attention, executive function, and processing speed, as well as other psychological factors such as quality of life, sleep, anxiety, and pain. Biological markers implicated in neurogenesis will be assessed through blood tests, direct questions, and with reference to medical history. After which, researchers will contact you if you are eligible for the second part of the study. It is hoped that findings from this study will assist researchers with optimising daily oncology care.

Interventions

Brief name: cross-section This observational study involves a large cross-section of non-CNS cancer patients and demographic matched healthy controls. Variables collected include cognitive performance, psychosocial functioning, medical history, apolipoprotein genotype, and peripheral plasma brain-derived neurotrophic factor (BDNF) levels. The mode of observation will be a single 90-120 minute visit to the study clinic per participant, at a single timepoint of data collection. This is noninclus

Brief name: cross-section This observational study involves a large cross-section of non-CNS cancer patients and demographic matched healthy controls. Variables collected include cognitive performance, psychosocial functioning, medical history, apolipoprotein genotype, and peripheral plasma brain-derived neurotrophic factor (BDNF) levels. The mode of observation will be a single 90-120 minute visit to the study clinic per participant, at a single timepoint of data collection. This is noninclusive of preliminary screening and liaising with potential participants.

Sponsors

Curtin University
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Study inclusion criteria require participants to be aged over 18 years old, currently live in Perth and Peel regions of Western Australia (or close enough), have been diagnosed with non-CNS cancer, be currently undergoing any treatment, and have a working proficiency of the English language. To provide a comparative baseline across assessments, 20-25% of the sample will consist of healthy controls that meet all other inclusion/exclusion criteria but are cancer-naive and are not undergoing treatment.

Exclusion criteria

Exclusion criteria preclude participation of individuals with premorbid developmental / cognitive dysfunction; premorbid neurodegenerative conditions; pregnancy; and central nervous system metastases. Enrolment in other trials may be an exclusion criterion - case by case basis.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026